Advertisement

Topics

Merck wins UK okay for Keytruda in lung cancer after price cut

14:13 EST 1 Dec 2016 | Reuters

LONDON (Reuters) - Britain's healthcare cost-effectiveness watchdog NICE has recommended use of Merck's immunotherapy drug Keytruda in certain lung cancer patients, after the U.S. drugmaker cut the price further for the state-run health service.

Original Article: Merck wins UK okay for Keytruda in lung cancer after price cut

NEXT ARTICLE

More From BioPortfolio on "Merck wins UK okay for Keytruda in lung cancer after price cut"

Quick Search
Advertisement
 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...